CO2021016794A2 - Tratamiento de la deficiencia de hierro en sujetos en riesgo de eventos adversos cardiovasculares - Google Patents

Tratamiento de la deficiencia de hierro en sujetos en riesgo de eventos adversos cardiovasculares

Info

Publication number
CO2021016794A2
CO2021016794A2 CONC2021/0016794A CO2021016794A CO2021016794A2 CO 2021016794 A2 CO2021016794 A2 CO 2021016794A2 CO 2021016794 A CO2021016794 A CO 2021016794A CO 2021016794 A2 CO2021016794 A2 CO 2021016794A2
Authority
CO
Colombia
Prior art keywords
risk
treatment
subjects
iron deficiency
adverse events
Prior art date
Application number
CONC2021/0016794A
Other languages
English (en)
Inventor
Claes Christian Strom
Tobias Sidelmann Christensen
Thomas Goldin Diness
Lars Lykke Thomsen
Original Assignee
Pharmacosmos Holding As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacosmos Holding As filed Critical Pharmacosmos Holding As
Publication of CO2021016794A2 publication Critical patent/CO2021016794A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al campo del tratamiento de la deficiencia de hierro con complejos de hierro y carbohidrato intravenosos tal como hierro isomaltósido en sujetos en riesgo de evento adverso cardiovascular, en donde el tratamiento de la deficiencia de hierro reduce la incidencia de, o el riesgo de, un evento adverso cardiovascular en el sujeto.
CONC2021/0016794A 2019-06-12 2021-12-10 Tratamiento de la deficiencia de hierro en sujetos en riesgo de eventos adversos cardiovasculares CO2021016794A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19179820 2019-06-12
PCT/EP2020/066270 WO2020249712A1 (en) 2019-06-12 2020-06-12 Treating iron deficiency in subjects at risk of cardiovascular adverse events

Publications (1)

Publication Number Publication Date
CO2021016794A2 true CO2021016794A2 (es) 2022-04-08

Family

ID=66857688

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0016794A CO2021016794A2 (es) 2019-06-12 2021-12-10 Tratamiento de la deficiencia de hierro en sujetos en riesgo de eventos adversos cardiovasculares

Country Status (9)

Country Link
JP (1) JP2022535602A (es)
KR (1) KR20220027948A (es)
CN (2) CN114286682A (es)
BR (1) BR112021025049A2 (es)
CO (1) CO2021016794A2 (es)
EA (1) EA202191858A1 (es)
IL (1) IL288843A (es)
MX (1) MX2021015415A (es)
WO (1) WO2020249712A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112024002150A2 (pt) * 2021-08-03 2024-04-30 Pharmacosmos Holding As Compostos de complexo de ferro para uso subcutâneo na terapia de deficiência de ferro em animais de companhia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3156075B1 (en) 2009-03-25 2020-10-14 Pharmacosmos Holding A/S An oligosaccharide and a process for preparation thereof
EP2537866A1 (en) 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
EP2822574A4 (en) 2012-03-05 2016-01-27 Luitpold Pharm Inc PROCESS FOR MODULATING PHOSPHORUS AND FGF23
KR102392441B1 (ko) * 2013-11-04 2022-05-02 케릭스 바이오파마슈티컬스 인코포레이티드 만성 신장 질환 환자의 유해한 심장 사건과 관련된 사망률 및 이환률 감소를 위한 시트르산 제2철
CN109069525A (zh) * 2016-03-16 2018-12-21 勃林格殷格翰国际有限公司 包含依帕列净的药物组合物及其用途
EP3681539A1 (en) 2017-09-11 2020-07-22 Pharmacosmos Holding A/S Iron complex compounds for therapeutic use

Also Published As

Publication number Publication date
KR20220027948A (ko) 2022-03-08
MX2021015415A (es) 2022-01-24
CN114286682A (zh) 2022-04-05
WO2020249712A1 (en) 2020-12-17
BR112021025049A2 (pt) 2022-02-22
JP2022535602A (ja) 2022-08-09
EA202191858A1 (ru) 2021-11-12
CN114364387A (zh) 2022-04-15
IL288843A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
SV2018005787A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
JOP20210291A1 (ar) مشتقات حمض إيتاكونيك واستخداماتها في علاج مرض التهابي أو مرض مصاحب لاستجابة مناعية غير مرغوب فيها
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
PH12019500513A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
MX2019005144A (es) Tratamiento de cáncer de mama positivo para her2.
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
CO2021016794A2 (es) Tratamiento de la deficiencia de hierro en sujetos en riesgo de eventos adversos cardiovasculares
MX2021001780A (es) Composiciones para el tratamiento de telas que comprenden capsulas de agente de beneficio.
BR112022003659A2 (pt) Composições e métodos de tratamento de doenças vasculares
CL2023001701A1 (es) Procedimiento de tratamiento del hierro fundido.
EA202092824A1 (ru) Комбинированная терапия
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
GB2529318A (en) Garment part, garment incorporating such garment part and method of manufacturing same
MX2020011164A (es) Compuesto de formamida, método de preparación para el mismo y aplicación del mismo.
EA202092045A1 (ru) Лечение и предупреждение преэклампсии
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
EA201791897A1 (ru) α-МИКРОГЛОБУЛИН ДЛЯ ИСПОЛЬЗОВАНИЯ В ЗАЩИТЕ ПОЧЕК ПРИ РАДИОНУКЛИДНОЙ ТЕРАПИИ
EA202090028A1 (ru) Способы уменьшения или предотвращения сердечно-сосудистых явлений у пациентов с сахарным диабетом ii типа
EA201791745A1 (ru) Производные тетрагидропиранилбензамида
CL2020001559A1 (es) Derivados glucosídicos de treprostinilo.
AR098670A1 (es) Inhibidor de sglt1